South Korea · Delayed Price · Currency is KRW Curocell Statistics
Total Valuation
Curocell has a market cap or net worth of KRW 526.32 billion. The enterprise value is 552.61 billion.
| Market Cap | 526.32B |
| Enterprise Value | 552.61B |
Important Dates
The last earnings date was Wednesday, August 13, 2025.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Curocell has 14.38 million shares outstanding.
| Current Share Class | 14.38M |
| Shares Outstanding | 14.38M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.52% |
| Owned by Insiders (%) | 33.52% |
| Owned by Institutions (%) | 10.33% |
| Float | 9.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 23.12 |
| P/TBV Ratio | 26.95 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -15.58 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -20.49 |
Financial Position
The company has a current ratio of 1.02, with a Debt / Equity ratio of 2.77.
| Current Ratio | 1.02 |
| Quick Ratio | 0.99 |
| Debt / Equity | 2.77 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.34 |
| Interest Coverage | -14.59 |
Financial Efficiency
Return on equity (ROE) is -86.66% and return on invested capital (ROIC) is -22.53%.
| Return on Equity (ROE) | -86.66% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -22.53% |
| Return on Capital Employed (ROCE) | -53.42% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -260.82M |
| Employee Count | 136 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Curocell has paid 1.10 million in taxes.
| Income Tax | 1.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.00% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +20.00% |
| 50-Day Moving Average | 32,876.00 |
| 200-Day Moving Average | 29,392.65 |
| Relative Strength Index (RSI) | 59.50 |
| Average Volume (20 Days) | 74,884 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -11.17M |
| Operating Income | -33.86B |
| Pretax Income | -35.47B |
| Net Income | -35.47B |
| EBITDA | -27.56B |
| EBIT | -33.86B |
| Earnings Per Share (EPS) | -2,511.78 |
Balance Sheet
The company has 36.82 billion in cash and 63.12 billion in debt, giving a net cash position of -26.30 billion or -1,828.66 per share.
| Cash & Cash Equivalents | 36.82B |
| Total Debt | 63.12B |
| Net Cash | -26.30B |
| Net Cash Per Share | -1,828.66 |
| Equity (Book Value) | 22.76B |
| Book Value Per Share | 1,602.98 |
| Working Capital | 685.09M |
Cash Flow
In the last 12 months, operating cash flow was -26.81 billion and capital expenditures -155.11 million, giving a free cash flow of -26.97 billion.
| Operating Cash Flow | -26.81B |
| Capital Expenditures | -155.11M |
| Free Cash Flow | -26.97B |
| FCF Per Share | -1,875.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Curocell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -6.74% |
| FCF Yield | -5.12% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |